Tumor Ablator Trials Travel Drug Path, But Sponsor Seeks Device Regulation
This article was originally published in The Gray Sheet
Executive Summary
Genetronics Biomedical is in talks with FDA to pursue clinical development of the MedPulsor tumor ablation system through a device regulatory route
You may also be interested in...
Inovio Halts Head And Neck Cancer Trials On Safety Concerns
Inovio Biomedical prematurely halted a pivotal study investigating its tumor ablation technology in head and neck cancer June 5 after an independent data monitoring committee raised concerns about adverse events
Inovio Halts Head And Neck Cancer Trials On Safety Concerns
Inovio Biomedical prematurely halted a pivotal study investigating its tumor ablation technology in head and neck cancer June 5 after an independent data monitoring committee raised concerns about adverse events
Cross-Labeling Challenges Lack Easy Fix; Data Exclusivity Incentive Floated
Data exclusivity extensions have been proposed as an incentive to encourage drug firms to amend product labeling in deference to related devices, but FDA and industry reps warn of complications inherent in this strategy